Novopharm Biotech of Canada has announced that it is in the final stages of negotiating a long-term worldwide agreement with a major multinational pharmaceutical company for the development, sale and distribution of biopharmaceutical products. First revenues from the sale of these products are expected within two years.
Michael Dan, chief executive of NB, said: "the company intends to leverage off the successful core business of its parent company, Novopharm Ltd, and create lasting value for its shareholders at a very low marginal cost. Funding for the innovative research program at NB will remain unchanged."
He continued that results of early clinical trials with the firm's first generation of products have been very encouraging, and a new generation of recombinant products is rapidly moving through scale-up and preclinical testing, with filing expected with the US Food and Drug Administration in the first quarter of 1997. The firm has also applied for a listing on the Toronto Stock Exchange.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze